Thursday, October 16, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > CEO Life > Health > Novo Nordisk shares surge after news of weight loss trial success

Novo Nordisk shares surge after news of weight loss trial success

in Health, News
Novo Nordisk shares surge after news of weight loss trial success
Share on LinkedinShare on WhatsApp

Novo Nordisk’s new weight loss drug, amycretin, is showing greater potential than Wegovy for weight loss, as its trial resulted in a 13.1% weight loss for participants after 12 weeks, compared to Wegovy’s 6%. Upon the news, the Danish pharmaceutical company’s shares jumped 8% on Thursday.

Novo Nordisk will began phase II of the trial later this year, with results anticipated in early 2026. The company also reported earlier this week that late-stage trials found that another weight loss drug, Ozempic, decreased the risk of kidney disease progression or death from kidney or cardiovascular complications by 24% in patients with diabetes who also had chronic kidney disease.

“As we always say, safety will be key and Novo are waiting to see results of the subcutaneous formulation before making a clinical plan,” said Yuri Khodjamirian, chief investment officer at Tema ETFs. “Overall, we think this bolsters Novo’s position as it now has several follow up agents to Ozempic/Wegovy, where the patent expires in 2031/32, led by Cagrisema and now Amycretin, to help evergreen their obesity franchise.”

Tags: Novo NordiskOzempicstock marketWegovyWeight loss drugs

Related Posts

Costco begins selling gold bars to customers
News

Gold rises 5% to reach another record high

CEOs of Wells Fargo and Pfizer call on the U.S. to promote innovation
News

CEOs of Wells Fargo and Pfizer call on the U.S. to promote innovation

Stellantis announces $13 billion U.S. investment
News

Stellantis announces $13 billion U.S. investment

Morgan Stanley penalizes employees for WhatsApp breaches
News

Morgan Stanley’s Q3 earnings jump 45%

BlackRock, Nvidia, xAI and Microsoft to acquire Aligned Data Centers
News

BlackRock, Nvidia, xAI and Microsoft to acquire Aligned Data Centers

LendingTree CEO Doug Lebda dies
News

LendingTree CEO Doug Lebda dies

46% of Americans who have invested in cryptocurrency say it’s done worse than expected
News

Crypto market shrinks by $150 billion following China’s retaliation

Google nixes $15 billion Bay Area development
News

Google announces $15 billion data center in India

CEO Jamie Dimon reports strong Q2 performance across all JPMorgan business lines
News

Jamie Dimon announces $1.5 Trillion security and resiliency initiative

Trade balances in China and the US are largely driven by domestic macro forces 
News

China calls for U.S. to withdraw 100% tariff threat

No Result
View All Result

Recent Posts

  • Gold rises 5% to reach another record high
  • CEOs of Wells Fargo and Pfizer call on the U.S. to promote innovation
  • Is China circumventing US tariffs via Mexico and Canada?
  • China’s retaliation cements a bitcoin reset
  • Stellantis announces $13 billion U.S. investment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.